Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM  
65.77
-1.15 (-1.72%)
4:20:00 PM EDT: $65.77 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.11B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$43.72 Million
Adjusted EPS-$0.64
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Rhythm Pharmaceuticals Inc. Stock, NASDAQ:RYTM

222 Berkeley Street, 12th floor, Boston, Massachusetts 02116-3748
United States of America
Phone: +1.857.264.4280
Number of Employees: 283

Description

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.